Highlights of weekly biotech stock moves

Basilea Pharmaceutica AG (SIX:BSLN) fell CHF9.10 to CHF104.90 last week after it said FDA confirmed additional Phase III data would be required to support U.S. approval of ceftobiprole to treat pneumonia. The company said it does not plan to conduct new Phase III trials without a U.S. partner.

Gilead Sciences Inc. (NASDAQ:GILD) added $0.76 to $82.94 on Friday after submitting an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for Sovaldi sofosbuvir to treat chronic HCV genotype 2 infection. The company already markets Sovaldi in the U.S., EU and Canada to treat HCV infection...